Neogen Corporation
NEOG
Positions held
Your positionsNEOG isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Neogen Corporation is positioned well in the healthcare sector, focusing on innovative medical devices that cater to a growing demand for health and safety solutions.
- In the latest quarter, Neogen reported a revenue increase of 7% compared to the previous quarter, reaching $225 million.
- The gross margin improved to 47.8%, up from 46.9% in the prior quarter, indicating better cost management and pricing power.
- Despite recent revenue growth, Neogen has faced challenges with negative profit margins, reflecting ongoing operational difficulties.
- The company reported a net income loss of $11.3 million in the latest quarter, continuing a trend of negative earnings.
- For the year 2026, Neogen is projected to have a net income loss of $7.9 million, highlighting persistent financial struggles.
Fundamentals
| Market cap | $2.55B | Enterprise value | $3.16B | Trailing P/E | — | Forward P/E | 30.82 |
| PEG | 0.66 | Price / book | 1.22 | Beta | 1.79 | Dividend yield | 0.00% |
| Revenue growth | 6.5% | Earnings growth | — | Gross margin | 47.4% | Operating margin | -0.8% |
| Profit margin | -6.3% | ROE | -2.7% | ROA | -0.1% | Debt / equity | 0.37 |
| Current ratio | 3.90 | Free cash flow | $38.94M | Analyst recommendation | buy | Mean target | $14.00 |
| 52w high | $14.26 | 52w low | $5.37 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $225M | $211M | $225M | $209M | $225M | — |
| Op margin | 1.4% | -1.6% | -2.4% | -7.7% | -5.9% | — |
| Net income | -$11.3M | -$17.0M | -$15.9M | $36.3M | -$612M | — |
| Gross margin | 47.8% | 46.9% | 47.5% | 45.4% | 41.2% | — |
| Gross profit | $108M | $99.0M | $107M | $95.0M | $92.9M | — |
| Operating income | $3.1M | -$3.3M | -$5.4M | -$16.1M | -$13.3M | — |
- Revenue +7% vs prior quarter ($225M vs $211M).
- Gross margin 47.8% (was 46.9% prior quarter).
- Operating margin expanded to 1.4%.
Yearly (6y)
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue | $870M | $895M | $924M | $822M | — |
| Op margin | -2.5% | -0.2% | 6.3% | 4.6% | — |
| Net income | -$7.9M | -$1.1B | -$9.4M | -$22.9M | — |
| Gross margin | 46.9% | 47.1% | 50.2% | 49.4% | — |
| Gross profit | $409M | $421M | $464M | $406M | — |
| Operating income | -$21.6M | -$1.7M | $58.6M | $37.5M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Neogen (NEOG) Received An FDA Warning Over Contaminated Veterinary Product
2026-10-08 · Neogen Eyes Up To Low-Double-Digit Revenue Growth by Fiscal 2031
2026-10-08 · The 5 Most Interesting Analyst Questions From Neogen’s Q3 Earnings Call
2026-10-08 · Neogen Investor Day Sets Path for Growth, 30% EBITDA Margin by 2031
2026-10-07 · Neogen Outlines Strategy for Growth, Innovation and Margin Expansion at 2026 Investor Day
2026-10-07 · Why Are Neogen (NEOG) Shares Soaring Today
2026-10-07 · Neogen (NEOG) Q1 2027 Earnings Call Transcript
2026-10-07 · This Food-Safety Stock Is Dropping After Earnings Beat. Growth Problems Are Lurking.
2026-10-07 · Neogen Soars 4% as Q1 Revenue Beat and Raised Guidance Show “Encouraging Progress”
2026-10-07 · Sector Update: Healthcare Stocks Flat to Higher Pre-Bell Wednesday
2026-10-07 · Neogen Corporation Q1 2027 Earnings Call Summary
2026-10-07 · 1 Unpopular Stock That Should Get More Attention and 2 We Find Risky
Price (daily)
Full chart · RSI · MACD · patternsOn Trade and Ticker